Brokers Set Expectations for Nuvation Bio FY2026 Earnings

Key Points

• HC Wainwright lowered its FY2026 EPS forecast for Nuvation Bio to a loss of $0.36 per share from $0.30, while maintaining a Buy rating and $21 price target. The revised estimate is slightly better than the $0.38-per-share consensus loss.
• Nuvation Bio’s latest quarterly results missed earnings expectations, reporting a $0.15-per-share loss versus the estimated $0.14 loss, though revenue of $31.69 million exceeded the $27.03 million forecast.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and $13 price target; however, insiders have sold 235,668 shares worth approximately $1.42 million over the past 90 days.

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for Nuvation Bio in a report issued on Friday, August 7th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.36) per share for the year, down from their previous estimate of ($0.30). HC Wainwright has a "Buy" rating and a $21.00 price target on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Nuvation Bio's Q4 2026 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.04) EPS and Q4 2027 earnings at ($0.02) EPS.

Nuvation Bio (NYSE:NUVB - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Nuvation Bio had a negative net margin of 88.18% and a negative return on equity of 46.59%. The firm had revenue of $31.69 million during the quarter, compared to analyst estimates of $27.03 million.

Other equities research analysts have also recently issued reports about the stock. Royal Bank Of Canada increased their price objective on shares of Nuvation Bio from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Friday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nuvation Bio in a report on Friday, July 17th. Wedbush reissued an "outperform" rating and set a $11.00 price objective on shares of Nuvation Bio in a research note on Thursday, July 23rd. Citigroup restated a "market outperform" rating on shares of Nuvation Bio in a research report on Wednesday, June 10th. Finally, Truist Financial upped their target price on Nuvation Bio from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday, July 7th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $13.00.

Nuvation Bio Trading Down 0.5%

NYSE:NUVB opened at $6.57 on Tuesday. The company has a market capitalization of $2.29 billion, a PE ratio of -14.93 and a beta of 1.52. The company has a quick ratio of 8.14, a current ratio of 8.37 and a debt-to-equity ratio of 0.96. Nuvation Bio has a 52-week low of $2.18 and a 52-week high of $9.75. The stock has a fifty day simple moving average of $5.79 and a 200-day simple moving average of $5.24.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Parallel Advisors LLC grew its holdings in Nuvation Bio by 51.9% in the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company's stock valued at $28,000 after purchasing an additional 2,597 shares during the period. Kestra Advisory Services LLC purchased a new position in Nuvation Bio during the fourth quarter worth approximately $71,000. KBC Group NV acquired a new position in shares of Nuvation Bio in the 1st quarter valued at $37,000. Patriot Financial Group Insurance Agency LLC acquired a new position in shares of Nuvation Bio in the 1st quarter valued at $43,000. Finally, Cornerstone Wealth Management LLC purchased a new stake in shares of Nuvation Bio during the 4th quarter valued at $100,000. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Nuvation Bio news, CFO Philippe Sauvage sold 47,668 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $6.01, for a total transaction of $286,484.68. Following the transaction, the chief financial officer owned 12,673 shares of the company's stock, valued at $76,164.73. This represents a 79.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kerry Wentworth sold 63,000 shares of the company's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $6.02, for a total value of $379,260.00. Following the completion of the transaction, the insider owned 53,000 shares of the company's stock, valued at $319,060. The trade was a 54.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 235,668 shares of company stock valued at $1,419,495. Insiders own 30.11% of the company's stock.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company's pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source